-- Shenzhen Salubris Pharmaceuticals' (SHE:002294) net profit attributable to shareholders in 2025 rose 8.3% to 651.5 million yuan from 601.6 million yuan a year earlier, according to a Shenzhen bourse filing on Tuesday.
Earnings per share climbed 7.4% year on year to 0.58 yuan from 0.54 yuan.
Operating revenue increased 8.5% to 4.35 billion yuan from 4.01 billion yuan in the prior year.
The pharmaceutical company's shares fell by over 3% during the midday trade.